Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 324.5% in April

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 145,600 shares, a growth of 324.5% from the March 31st total of 34,300 shares. Based on an average daily volume of 264,000 shares, the short-interest ratio is presently 0.6 days. Currently, 9.1% of the company’s stock are sold short.

Aptevo Therapeutics Price Performance

Shares of APVO remained flat at $0.68 during mid-day trading on Thursday. The stock had a trading volume of 367,850 shares, compared to its average volume of 220,565. Aptevo Therapeutics has a 52 week low of $0.67 and a 52 week high of $90.20. The business’s fifty day moving average price is $4.31 and its 200-day moving average price is $7.42.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Aptevo Therapeutics in a research report on Thursday, April 18th. They set a “sell” rating for the company.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned approximately 10.72% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.